A lipidated Anti-Tat antibody enters living cells and blocks HIV-1 viral replication

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 14, Issue 3, 1997, Pages 193-203

  Cruikshank, William W ^a   Doctrow, Susan R ^b   Falvo, Melissa S ^a   Huffman, Karl ^b   Maciaszek, Joseph ^a   Viglianti, Gregory ^a   Raina, Jay ^c   Kornfeld, Hardy ^a   Malfroy, Bernard ^b  

^a BOSTON UNIVERSITY   (United States)

^b Eukarion Inc   (United States)

^c AGMED Inc   (United States)

Author keywords

Anti Tat antibodies; Human immunodeficiency virus type I (HIV 1; Immunotherapy; Intracellular antibodies; Lipidation

Indexed keywords

PROTEIN ANTIBODY; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; PRIORITY JOURNAL; VIRUS GENE; VIRUS ISOLATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030945916     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199703010-00001     Document Type: Article

References (30)

1. Hirsch MS. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J Infect Dis 1990;161:845-57.
2. Johnston MI, Hoth DF. Present status and future prospects for HIV therapies. Science 1993;260:1286-93.
3. Fischl MA, Richman DD, Grieco HM. The efficacy of asidothymidine (AZT)J in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
4. Volberding PA, Lagalros SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995;333:401-7.
5. Kinloch-De Loes S. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13.
6. Chen SY, Bagley J, Marasco WA. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther 1994;5:595-601.
7. Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994;91:5075-9.
8. Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 1993;90:7889-93.
9. Chen SY, Khouri Y, Bagley J, Marasco WA. Combined intra-and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci USA 1994;91:5932-6.
10. Maciejewski JP, Weichold FF, Young NS, et al. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med 1995;1:667-73.
11. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 1994;14:1542-51.
12. Derse D, Newbold SH. Mutagenesis of EIAV TAT reveals structural features essential for transcriptional activation and TAR element recognition. Virology 1993;194:530-6.
13. Ohana B, Moore PA, Ruben SM, Southgate CD, Green M, Rosen CA. The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genes. Proc Natl Acad Sci USA 1993;90:138-42.
14. Nakane PK, Kawaoi A. Peroxidase-labeled antibody - a new method of conjugation. J Histochem 1974;15:1079-84.
15. Male D, Champion B, Cooke A. Antibody. In: Advanced Immunology, Hadjidimitriadou H, ed. New York: Gower Medical, 1987:2.2-2.3.
16. Johnson VA, Byington RE. Quantitative assays for virus infectivity. In: Techniques in HIV research, Aldovini A, Walker BD, eds. New York: Stockton Press, 1990:71076.
17. Seed B, Sheen JY. A simple phase-extraction assay for chloramphenicol acyltransferase activity. Gene 1988;67:271-7.
18. Maciaszek JW, Talmage DA, Viglianti GA. Synergistic activation of simian immunodeficiency virus and human immunodeficiency virus type I transcription by retinoic acid and phorbol ester through an NF-kB-independent mechanism. J Virol 1994;68:6598-604.
19. Leonard J, et al. The NF-kB binding sites in the human immunodeficiency virus type I long terminal repeat are not required for virus infectivity. J Virol 1989;63:4919-24.
20. Southgate CD, Green MR. The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev 1991;5:2496-507.
21. Viglianti GA, Mullins JI. Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type I. J Virol 1988;62:4523-32.
22. Johnson VA, Byington RE, Kaplan JC. Reverse transcriptase (RT) activity assay. In: Techniques in HIV research, Aldovini A, Walker BD, eds. New York: Stockton Press, 1990:98-102.
23. Johnson VA, Walker BD, Barlow MA, Paradis TJ, Chou T-C, Hirsch MS. Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3′-azido-3′deoxythymidine. Antimicrob Agents Chemother 1989;33:53-7.
24. Smith SD, Shatske M, Cohen PS, Warnke R, Link MP, Glader BE. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 1984;44:5657-60.
25. Ciminal V, Felber BK, Campbell M, Pavlakis GN. A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res Hum Retrovirus 1990;6:1281-9.
26. Perez UL, Rowe T, Justement JS, Butera ST, June CH, Folks TM. An HIV-1 infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. J Immunol 1991;147:3145-8.
27. Butera ST, Roberts BD, Folks TM. Regulation of HIV-1 expression by cytokine networks in a CD4+ model of chronic infection. J Immunol 1993;150:625-34.
28. Marasco WA. Spatial association of HIV-1 tat protein and the nucleolar transport protein B23 in stably transfected Jurkat T-cells. Arch Virol 1994;139:133-54.
29. Brake DA, Goudsmit J, Krone WJ, et al. Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1. J Virol 1990;64:962-5.
30. Phillips NC, Gagne L, Tsoukas C, Dahman J. Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status. J Immunol 1994;152:3168-74.